Repligen To Present at 36th Annual J.P. Morgan Healthcare Conference
December 29 2017 - 1:47PM
Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing-focused
company delivering technology innovation to improve biologic drug
manufacturing flexibility and efficiency, today announced that the
Company will be presenting at the 36th Annual J.P. Morgan
Healthcare Conference, being held January 8-11, 2018 in San
Francisco. Tony J. Hunt, President and CEO of Repligen, will
present a company overview on Tuesday, January 9 at 4:00 p.m.
PT.
A live webcast of the event will be accessible through the
Investor Relations section of Repligen’s website. This webcast will
be archived for a period of time following the live event.
About Repligen CorporationRepligen Corporation
(NASDAQ:RGEN) is a global bioprocessing company that develops and
commercializes highly innovative products that deliver cost and
process efficiencies to biological drug manufacturers worldwide.
Our portfolio includes protein products (Protein A affinity
ligands, cell culture growth factors), chromatography products
(OPUS® pre-packed columns, chromatography resins, ELISA kits) and
filtration products (including XCell™ ATF systems, TangenX™ Sius™
flat sheet TFF cassettes, and Spectrum KrosFlo™ hollow fiber TFF
cartridges and systems). The Protein A ligands and growth factor
products that we produce are key components of Protein A affinity
resins and cell culture media, respectively. Protein A affinity
resins are the industry standard for downstream separation and
purification of monoclonal antibody-based therapeutics. Growth
factors are used in upstream processes to accelerate cell growth
and productivity. Our innovative line of OPUS® chromatography
columns, used in downstream processes for bench-scale through
clinical-scale purification needs, are delivered pre-packed to our
customers with their choice of resin and to their bed height
preferences. Our XCell™ ATF Systems, available in stainless steel
and single-use configurations, continuously eliminate waste from a
bioreactor to concentrate cells and significantly increase
productivity in upstream processes. Single-use Sius™ TFF cassettes
and hardware are used for biologic drug concentration in downstream
filtration processes. Spectrum KrosFlo™ TFF cartridges and systems
are used in both upstream and downstream filtration processes.
Repligen’s corporate headquarters are in Waltham, MA (USA), with
additional administrative and manufacturing operations in
Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden and Weingarten,
Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024